Total Payments
$1.0M
2024 Payments
$549,079
Companies
26
Transactions
396
Medicare Patients
807
Medicare Billing
$99,368
Payment Breakdown by Category
Other$593,535 (57.9%)
Consulting$339,395 (33.1%)
Travel$57,431 (5.6%)
Research$29,141 (2.8%)
Food & Beverage$5,436 (0.5%)
Education$195.91 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $568,510 | 61 | 55.5% |
| Consulting Fee | $339,395 | 166 | 33.1% |
| Travel and Lodging | $57,431 | 55 | 5.6% |
| Unspecified | $29,141 | 29 | 2.8% |
| Honoraria | $25,025 | 4 | 2.4% |
| Food and Beverage | $5,436 | 80 | 0.5% |
| Education | $195.91 | 1 | 0.0% |
Payments by Type
General
$995,992
367 transactions
Research
$29,141
29 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $565,793 | 51 | $0 (2024) |
| F. Hoffmann-La Roche AG | $100,229 | 75 | $0 (2023) |
| GENZYME CORPORATION | $69,913 | 32 | $0 (2023) |
| SANOFI-AVENTIS U.S. LLC | $54,816 | 55 | $0 (2021) |
| Horizon Therapeutics plc | $47,009 | 34 | $0 (2023) |
| ARGENX US, INC. | $43,694 | 32 | $0 (2024) |
| Novartis Pharma AG | $22,416 | 11 | $0 (2023) |
| Hoffmann-La Roche Limited | $21,394 | 9 | $0 (2022) |
| Chugai Pharmaceutical Co., Ltd. | $17,259 | 7 | $0 (2019) |
| AbbVie Inc. | $15,446 | 16 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $549,079 | 41 | Amgen Inc. ($529,362) |
| 2023 | $112,033 | 70 | ARGENX US, INC. ($31,875) |
| 2022 | $68,110 | 46 | Amgen Inc. ($18,745) |
| 2021 | $22,954 | 12 | SANOFI-AVENTIS U.S. LLC ($10,736) |
| 2020 | $42,661 | 28 | SANOFI-AVENTIS U.S. LLC ($13,600) |
| 2019 | $118,592 | 100 | F. Hoffmann-La Roche AG ($52,144) |
| 2018 | $54,392 | 59 | GENZYME CORPORATION ($13,731) |
| 2017 | $57,312 | 40 | F. Hoffmann-La Roche AG ($25,020) |
All Payment Transactions
396 individual payment records from CMS Open Payments — Page 1 of 16
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/24/2024 | Amgen Inc. | TAVNEOS (Drug) | Consulting Fee | Cash or cash equivalent | $2,608.32 | General |
| Category: Inflammation | ||||||
| 11/14/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $109.69 | General |
| 11/08/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $101.74 | General |
| Category: Inflammation/Rare Disease | ||||||
| 10/29/2024 | ARGENX US, INC. | — | Consulting Fee | Cash or cash equivalent | $250.00 | General |
| 10/29/2024 | ARGENX US, INC. | — | Consulting Fee | Cash or cash equivalent | $125.00 | General |
| 10/21/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $1,960.00 | General |
| Category: IMMUNOLOGY | ||||||
| 10/09/2024 | ARGENX US, INC. | VYVGART (Drug) | Consulting Fee | Cash or cash equivalent | $1,125.00 | General |
| Category: Immunology | ||||||
| 10/09/2024 | ARGENX US, INC. | VYVGART (Drug) | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: Immunology | ||||||
| 10/09/2024 | ARGENX US, INC. | VYVGART (Drug) | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: Immunology | ||||||
| 10/09/2024 | ARGENX US, INC. | VYVGART (Drug) | Consulting Fee | Cash or cash equivalent | $375.00 | General |
| Category: Immunology | ||||||
| 10/09/2024 | ARGENX US, INC. | VYVGART (Drug) | Consulting Fee | Cash or cash equivalent | $125.00 | General |
| Category: Immunology | ||||||
| 10/09/2024 | ARGENX US, INC. | VYVGART (Drug) | Consulting Fee | Cash or cash equivalent | $125.00 | General |
| Category: Immunology | ||||||
| 10/09/2024 | ARGENX US, INC. | VYVGART (Drug) | Consulting Fee | Cash or cash equivalent | $125.00 | General |
| Category: Immunology | ||||||
| 09/24/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $54.15 | General |
| Category: Inflammation/Rare Disease | ||||||
| 09/02/2024 | Amgen Inc. | TAVNEOS (Drug) | Consulting Fee | Cash or cash equivalent | $1,304.16 | General |
| Category: Inflammation | ||||||
| 08/18/2024 | Amgen Inc. | UPLIZNA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $7,280.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 08/18/2024 | Amgen Inc. | UPLIZNA (Biological) | Travel and Lodging | In-kind items and services | $700.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 08/18/2024 | Amgen Inc. | UPLIZNA (Biological) | Travel and Lodging | In-kind items and services | $522.90 | General |
| Category: Inflammation/Rare Disease | ||||||
| 08/18/2024 | Amgen Inc. | UPLIZNA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $60.45 | General |
| Category: Inflammation/Rare Disease | ||||||
| 08/18/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $48.76 | General |
| Category: Inflammation/Rare Disease | ||||||
| 08/18/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $13.45 | General |
| Category: Inflammation/Rare Disease | ||||||
| 08/12/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $102.85 | General |
| Category: Inflammation/Rare Disease | ||||||
| 07/09/2024 | Amgen Inc. | UPLIZNA (Biological) | Consulting Fee | Cash or cash equivalent | $4,675.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 06/14/2024 | Amgen Inc. | UPLIZNA (Biological) | Travel and Lodging | In-kind items and services | $167.36 | General |
| Category: Inflammation/Rare Disease | ||||||
| 06/14/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $72.17 | General |
| Category: Inflammation/Rare Disease | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| CAIN457C22301 | Novartis Pharma AG | $10,384 | 3 |
| Ph3 Avacopan in subjects with ANCA-associated vasculitis pivotal study ADVOCATE | Amgen Inc. | $4,451 | 1 |
| CAIN457C22301 (REPLENISH) | Novartis Pharma AG | $2,945 | 2 |
| A Phase 2 randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of efgartigimod in adult patients with Anti-neutrophil cytoplasmic antibody(ANCA) Associated Vasculitis (AAV) | ARGENX US, INC. | $2,400 | 1 |
| Clinical outcomes of patients with giant cell arteritis treated with tocilizumab in real-world clinical practice decreased incidence of new visual manifestations | F. Hoffmann-La Roche AG | $1,572 | 1 |
| CHARACTERISTICS OF GIANT CELL ARTERITIS FLARES AFTER SUCCESSFUL TREATMENT WITH TOCILIZUMAB RESULTS FROM THE LONG-TERM EXTENSION OF A RANDOMIZED CONTROLLED PHASE 3 TRIAL | F. Hoffmann-La Roche AG | $1,313 | 1 |
| A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sarilumab in Patients With Giant Cell Arteritis | SANOFI US SERVICES INC. | $976.24 | 9 |
| A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF TOCILIZUMAB VERSUS PLACEBO IN PATIENTS WITH SYSTEMIC SCLEROSIS | F. Hoffmann-La Roche AG | $575.00 | 2 |
| A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis (GCA): Study design and patient selection | SANOFI-AVENTIS U.S. LLC | $265.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 156 | 219 | $130,169 | $23,516 |
| 2022 | 4 | 233 | 301 | $160,535 | $30,439 |
| 2021 | 4 | 205 | 247 | $114,254 | $25,147 |
| 2020 | 4 | 213 | 255 | $106,337 | $20,267 |
Total Patients
807
Total Services
1,022
Medicare Billing
$99,368
Procedure Codes
15
All Medicare Procedures & Services
15 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 100 | 160 | $98,462 | $17,925 | 18.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 38 | 41 | $17,217 | $2,948 | 17.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 18 | 18 | $14,490 | $2,643 | 18.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 112 | 153 | $93,139 | $18,073 | 19.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 84 | 107 | $44,283 | $7,847 | 17.7% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 17 | 17 | $13,573 | $2,881 | 21.2% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2022 | 20 | 24 | $9,540 | $1,638 | 17.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 84 | 108 | $59,373 | $12,820 | 21.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 93 | 108 | $38,603 | $8,764 | 22.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 13 | 13 | $10,257 | $2,253 | 22.0% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 15 | 18 | $6,021 | $1,309 | 21.7% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 77 | 105 | $52,034 | $8,975 | 17.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 81 | 93 | $31,666 | $5,543 | 17.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 19 | 19 | $15,471 | $3,184 | 20.6% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 36 | 38 | $7,166 | $2,564 | 35.8% |
About Dr. John Stone, M.D
Dr. John Stone, M.D is a Internal Medicine healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/11/2006. The National Provider Identifier (NPI) number assigned to this provider is 1053346924.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Stone, M.D has received a total of $1.0M in payments from pharmaceutical and medical device companies, with $549,079 received in 2024. These payments were reported across 396 transactions from 26 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($568,510).
As a Medicare-enrolled provider, Stone has provided services to 807 Medicare beneficiaries, totaling 1,022 services with total Medicare billing of $99,368. Data is available for 4 years (2020–2023), covering 15 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Rheumatology
- Location Boston, MA
- Active Since 07/11/2006
- Last Updated 12/13/2012
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1053346924
Products in Payments
- UPLIZNA (Biological) $520,998
- Actemra (Biological) $146,883
- KEVZARA (Biological) $51,207
- KEVZARA (Drug) $49,903
- UPLIZNA (Drug) $36,912
- VYVGART (Drug) $22,919
- TAVNEOS (Drug) $21,186
- Tavneos (Drug) $17,585
- COSENTYX (Biological) $15,601
- SAR443122 (Drug) $13,155
- AIN457A_COSENTYX_DERMATOLOGY (Biological) $6,816
- NO PRODUCT DISCUSSED (Drug) $2,954
- VYVGART HYTRULO (Drug) $2,400
- Rituxan (Biological) $1,277
- RIABNI (Biological) $1,160
- VONJO (Drug) $962.00
- Non-Covered Product (Drug) $420.00
- ORENCIA (Biological) $175.00
- KRYSTEXXA (Biological) $128.38
- TALTZ (Drug) $13.70
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Boston
Michael Mendelsohn, M.d, M.D
Internal Medicine — Payments: $4.6M
Internal Medicine $4.6M
David Schenkein, Md, MD
Internal Medicine — Payments: $4.0M
Internal Medicine $4.0M
Dr. John Fallon, M.d, M.D
Internal Medicine — Payments: $2.5M
Internal Medicine $2.5M
Dr. David Scadden, Md, MD
Internal Medicine — Payments: $2.2M
Internal Medicine $2.2M
Dr. James Januzzi, Md, MD
Internal Medicine — Payments: $1.8M
Internal Medicine $1.8M
Dr. Marilyn Pike, Md Phd, MD PHD
Internal Medicine — Payments: $1.5M
Internal Medicine $1.5M